Financials · Accident & Health Insurance

CNO CNO Financial Group, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1224608155 filings
Russell 2000

CNO at a glance

CNO Financial Group, Inc. (CNO, SEC CIK 1224608) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CNO Financial Group, Inc. (CNO) reported revenue of $4.5 billion (up 0.9% from FY2024) and net income of $229.3 million. Diluted EPS was $2.30.
  • As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding CNO Financial Group, Inc. (CNO) shares worth $2.7 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Johnson Eric R. on November 17, 2026 of 20,170 shares at $56.59 per share.
  • In the last 90 days, CNO insiders reported 0 open-market purchases ($0) and 14 open-market sales ($4.8M) on Form 4, a net sale of $4.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$4.5B
+0.9% vs prior year
Insiders · 90 days
0 buys · 14 sells
Net −$4.8M
13F holders
35 funds
$2.7B · +3 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 5.03 · Item 1.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Insurance products sales and administration via Consumer and Worksite Divisions, leveraging exclusive agents, independent producers, and direct marketing
  • Strategic shift: Announced 2025 exit from fee services in Worksite Division to focus on core insurance business, expected by mid-2026
  • New product emphasis: Launched death benefit rider on fixed indexed annuities with guaranteed lifetime income in 2025
  • Notable quantitative metric: Premium collections $4.59B in 2025, up from $4.38B in 2024, with fixed indexed annuities representing 38% ($1.74B) of total premiums
  • Unique fact: Discontinued ceding 25% of new long-term care business to reinsurer starting Oct 1, 2024

Risk Factors

  • Interest rate risk with fixed income securities duration 7.5 years vs liabilities 8.1 years
  • Fair value decline $691.7 million if interest rates rise 10% from Dec 31, 2025 levels
  • Inflation impact on insurance policy benefits linked to medical cost increases
  • Equity securities market price volatility risk managed by limiting portfolio size
  • Equity-linked investments matched to fixed indexed annuity liabilities to hedge value changes

Management Discussion & Analysis

  • Total revenue (insurance product margin) $1,067.6M in 2025, up 2.6% YoY from $1,040.0M in 2024
  • Operating margin (income from insurance products / total margin) ~42.7% in 2025 vs. ~40.8% in 2024 (456.3/1067.6 vs 424.7/1040.0)
  • Best segment: Health margin $556.6M in 2025, up 7.7% YoY; Worst segment: Annuity margin $238.6M in 2025, down 13.0% YoY
  • Net operating income $439.2M in 2025 vs $429.3M in 2024; Net income $229.3M in 2025 vs $420.8M in 2024 due to non-operating losses including $101.9M goodwill impairment
  • Cash flow & capital allocation: No direct buyback/dividend/capex numbers disclosed; $20.3M in TechMod initiative expenses impacting cash flow
  • Forward outlook: Management highlighting technology modernization completion post-2025; risks include investment losses, mortality/morbidity assumption changes, and regulatory/tax changes impacting deferred tax assets

AI summary of the CNO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Net operating income $179.1M, up from $127.2M YoY
  • Operating ROE 14.1% vs 11.2% YoY; expense ratio 18.6% vs 19.2%
  • Best segment: life margin $96.0M vs $70.6M; worst: health margin $149.1M vs $157.0M
  • Cash $230.7M vs $150M minimum; $180.0M share repurchases and $50.4M dividends
  • 2026 EPS guidance raised to $5.05-$5.15; Medicare Advantage sales down 7.9% and fee guidance reduced to $25M

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • General business risks could materially affect CNO’s operations
  • Financial risks could materially affect CNO’s financial condition
  • Previously disclosed risks remain applicable to CNO’s businesses

AI summary of the CNO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • New Series G preferred stock designation supports CNO’s amended shareholder rights plan
  • Series F preferred stock elimination removes the prior rights-plan share class

Item 1.01: Entry into a Material Definitive Agreement

  • Section 382 rights agreement extended to November 13, 2029, preserving protection for CNO’s tax net operating loss carryforwards
  • 4.99% ownership threshold limits share accumulation without Board approval, potentially restricting takeover activity and large investor positions
Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • CNO announced financial results for the quarter ended September 30, 2026
  • Quarterly Financial Supplement provides detailed operating and financial metrics

Item EX-99.3: Item EX-99.3

  • 3Q26 operating EPS $1.90, up 47%; excluding actuarial items, EPS $1.42, up 48%
  • Full-year 2026 operating EPS guidance raised to $5.05-$5.15, a 9% midpoint increase

Item EX-99.1: Item EX-99.1

  • 3Q26 net operating income $179.1M, up 41%; operating EPS $1.90, up 47% year over year
  • Results included $44.9M favorable actuarial-review impact, making underlying operating EPS $1.42

Item EX-99.2: Item EX-99.2

  • 3Q26 net income $161.1M, or $1.71 diluted EPS, versus $23.1M and $0.24 in 3Q25
  • Net operating income $179.1M, or $1.90 diluted EPS, reflects strong underlying insurance performance
Filed Sep 1, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor briefing presentation focuses on CNO’s Worksite Division and Medicare business
  • Presentation available through CNO’s Investor Relations website and Exhibit 99.1

AI summaries of CNO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CNO

Don't miss the next CNO filing

  • Alerts as it files. A push when CNO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CNO, by share count.
  • Ask anything. An AI agent that reads every CNO filing and answers with sources.

CNO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Zimpfer Matthew J.GNov 18, 2026-
Johnson Eric R.SellNov 17, 2026$56.59
Johnson Eric R.MNov 17, 2026-
Johnson Eric R.MNov 17, 2026$21.06
Zimpfer Matthew J.SellNov 16, 2026$57.05
Williams Jeremy D.MSep 16, 2026-
Williams Jeremy D.SellSep 16, 2026$55.72
Williams Jeremy D.MSep 16, 2026$23.33

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$4.1B$4.4B$4.5B
Operating Income$459.5M$550.8M$553.2M
Net Income$276.5M$404.0M$229.3M
Op. Margin11.1%12.4%12.3%
Net Margin6.7%9.1%5.1%
Balance Sheet
Total Assets$35.1B$37.9B$38.8B
Equity-$2.5B$2.6B
ROE-16.2%8.7%
Per Share
EPS$2.40$3.74$2.30
Cash Flow
Operating CF$582.9M$627.7M$675.7M

Source: XBRL data in CNO Financial Group, Inc. (CNO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CNO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CNO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202635$2.66B
Q2 202632$2.61B
Q1 202631$2.01B
Q4 202530$1.91B
Q3 202530$2.01B
Q2 202530$1.95B
Q1 202527$1.61B
Q4 202422$1.33B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CNO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
8-KNov 13, 2026Analysis-
13F-HRNov 10, 2026-
10-QNov 5, 2026Analysis
8-KOct 29, 2026Analysis-
4Sep 16, 2026--
4Sep 2, 2026--
4Sep 2, 2026--
8-KSep 1, 2026Analysis-
13F-HRAug 12, 2026-
10-QAug 6, 2026Analysis
8-KJul 30, 2026Analysis-
4Jul 1, 2026--
4Jul 1, 2026--
4Jun 11, 2026--
4Jun 8, 2026-
4Jun 4, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
13F-HRMay 13, 2026-
8-KMay 13, 2026Analysis
4May 13, 2026-
4May 13, 2026-

Related Financials companies

All Financials →

CNO SEC filings: frequently asked questions

Are CNO insiders buying or selling?

In the last 90 days, CNO Financial Group, Inc. (CNO) officers, directors and 10% owners reported no open-market purchases and 14 open-market sales worth $4.8 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CNO stock?

As of September 30, 2026, the largest CNO Financial Group, Inc. (CNO) holders among the 13F filers tracked by SignalX were BlackRock ($709.1 million), Vanguard Portfolio Management LLC ($352.2 million), State Street Corp ($220.3 million), Vanguard Capital Management LLC ($214.0 million), Franklin Resources ($197.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CNO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CNO Financial Group, Inc. (CNO) reported revenue of $4.5 billion (up 0.9% from FY2024) and net income of $229.3 million. Diluted EPS was $2.30. The figures come from the XBRL data in the 10-K.

What are the main risks in CNO's latest 10-K?

In the 10-K filed February 24, 2026, CNO Financial Group, Inc. (CNO) flagged: Interest rate risk with fixed income securities duration 7.5 years vs liabilities 8.1 years. Fair value decline $691.7 million if interest rates rise 10% from Dec 31, 2025 levels. (AI summary of the Risk Factors section.)

What did CNO report in its latest 8-K?

CNO Financial Group, Inc. (CNO) filed an 8-K on November 13, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws) and Item 1.01 (Entry into a Material Definitive Agreement). New Series G preferred stock designation supports CNO’s amended shareholder rights plan.

What are the latest CNO SEC filings?

CNO Financial Group, Inc. (CNO) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 18, 2026.

What is CNO's SEC CIK number?

CNO Financial Group, Inc. (CNO)'s SEC Central Index Key (CIK) is 1224608. EDGAR lists every CNO filing under that number.

Ask anything about CNO

The research agent reads CNO's filings, financials, insider trades and 13F holders, then answers with sources.